
|Slideshows|October 28, 2016
ANA 2016: Selective Neuronal Dysfunction
Author(s)Samantha J. Peterson
Data blitz presentations at ANA 2016 featured studies on neuronal dysfunction and degeneration in ALS, Parkinson disease, transverse myelitis, & more.
Advertisement
Presentations at the ANA 2016 Selective Neuronal Dysfunction and Degeneration session included studies on neuronal loss in multiple system atrophy, deep brain stimulation in early Parkinson disease, treatment of transverse myelitis with dalfampridine, and a phase I trial of MSC therapy for ALS.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
3
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
4
CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis
5










